BRAF and melanoma: In addition, RMC-6236 is also active in patients whose tumors harbored Q61X mutations (PDAC and melanoma) and V600E BRAF–mutated colorectal cancer with emergent RAS mutations following treatment with BRAF and epidermal growth factor receptor inhibitors.35 Considering the highest risk of death of patients with PDAC and G12D, G12V, and other KRAS mutations, if the activity of such inhibitors is confirmed, the outcomes of these patients may improve.